

# 2-((4-((E)-1-(hydroxyimino)ethyl)phenyl)amino)-2-oxoethyl cinnamate

Ioanna-Chrysoula Tsopka <sup>1</sup> and Dimitra Hadjipavlou-Litina <sup>1,\*</sup>

<sup>1</sup>Department of Pharmaceutical Chemistry, School of Pharmacy, Faculty of Health Sciences, Aristotle University of Thessaloniki, Thessaloniki 54124, Greece; itsopkaa@pharm.auth.gr

\*Correspondence: hadjipav@pharm.auth.gr; Tel.: +30-231-099-7627; Fax: +30-231-099-7679

<b>Figure S1:</b> <sup>1</sup> H NMR spectrum of compound <b>5</b> .....	2
<b>Figure S2:</b> <sup>13</sup> C NMR spectrum of compound <b>5</b> .....	3
<b>Figure S3:</b> HR-MS spectrum of compound <b>5</b> .....	4
<b>Figure S4:</b> LC-MS spectrum of compound <b>5</b> .....	5




Figure S1: <sup>1</sup>H NMR spectrum of compound 5.




Figure S2: <sup>13</sup>C NMR spectrum of compound 5.





Figure S3: HR-MS spectrum of compound 5.



**Figure S4:** LC-MS spectrum of compound 5.